IO Vancomycin Administration in TKA

Phase 4Not Yet RecruitingNCT07633418

University of California, San Diego30 enrolled

Overview

This is a prospective, single-center, open-label study evaluating systemic vancomycin levels following preoperative intraosseous administration in patients undergoing primary unilateral total knee arthroplasty. Eligible participants will receive preoperative intraosseous vancomycin (500 mg in 100 mL saline) as part of standard perioperative infection prophylaxis. The study is open-label due to the nature of the intervention. Blood samples will be collected at predefined time points intraoperatively to measure serum vancomycin concentrations. Patients will be randomized to either a tourniquet or no tourniquet for these blood draws.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Total Knee Arthroplasty

Interventions

Intraosseous Vamcomycin AdministrationDRUG

IO Vancomycin Administration in TKA

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Is a patient over the age of 18 receiving treatment at UC San Diego 2. Is undergoing primary unilateral total knee arthroplasty 3. Is able to provide consent 4. Is candidate for IO administration of Vancomycin Exclusion Criteria: 1. Has had a previous surgery on the knee of interest (with the exception of arthroscopy) 2. Has a BMI \>35 3. Has a contraindication to receiving vancomycin, cefepime, or cefazolin (i.e. allergy) 4. Has diabetes with A1c \>7.5% (unless with controlled fructosamine) 5. Is immunocompromised/immunosuppressed (i.e. due to HIV, hepatitis C, end-stage renal disease, post-transplant status, chemotherapy or radiation therapy within 6 months of surgery, immunomodulating medications) 6. Has a history of active infection 7. Inability to provide consent 8. Prisoner 9. Pregnant women

Locations (1)

UC San Diego

San Diego, California, United States

Outcomes

Primary Outcomes

Serum Vancomycin Levels

Serum Vancomycin Levels following IO Vancomycin administration

Time frame: From administration up to 30 minutes post-administration.

Central Contacts

Dominic Baun

CONTACT

858-534-8268 jbaun@health.ucsd.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.